logo-loader
viewQ BioMed Inc.

Q BioMed discovers two key biomarkers in study of pediatric nonverbal autism

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive Investors the New York-based biotech has made a "tremendous" discovery in the first two biomarkers for pediatric nonverbal autism.

Corin says this allows the company a greater chance of success in its clinical study for drug candidate QBM-001, as these new biomarkers clearly define the patient population.

Quick facts: Q BioMed Inc.

Price: 2.25 USD

OTCMKTS:QBIO
Market: OTCQB
Market Cap: $46.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed infuses first patient with its FDA-approved cancer...

Q BioMed Inc. (OTCQB:QBIO) CEO Denis Corin tells Proactive the New York-based biotech company, has dosed its first patient in a commercial setting with its FDA approved non-opioid drug Strontium89 for patients with pain from metastatic bone cancer. Corin says the company is working on making...

3 weeks, 2 days ago

2 min read